Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Clinical trial NCT06056921 · RECRUITING

Trial details

NCT number: NCT06056921
Sponsor: Chongqing Precision Biotech Co., Ltd
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

SLE (Systemic Lupus)Sjogren's Syndrome Systemic Scleroderma Dermatomyositis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Start date: 2023-08-31
Primary completion: 2025-12-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.